Recently, AstraZeneca's SGLT2 inhibitor "dapagliflozin tablets" received approval for a new indication for adult patients with chronic kidney disease (CKD) at risk of disease progression (regardless of whether these patients have type 2 diabetes) , to reduce the estimated risk of persistent decline in glomerular filtration rate, progression to end-stage renal disease, cardiovascular death, and heart failure hospitalization.
Dapagliflozin is the first sodium-glucose cotransporter-2 (SGLT2) inhibitor, which is administered orally once daily. It is currently approved for 4 indications globally: type 1 diabetes, type 2 diabetes, and heart disease with reduced ejection fraction. aging and chronic kidney disease. In China, dapagliflozin was first approved in March 2017 for the treatment of type 2 diabetes, and has since been approved for heart failure with reduced ejection fraction and chronic kidney disease.
Contact Person: Mrs. Angie Zhang